Oral semaglutide: difference between revisions
Diff·revision 10 → 11·23:03, 30 Jan 2025
Difference between revision 10 and revision 11 of Oral semaglutide. 7 lines changed; the page grew by 278 bytes.
| Revision 10 — 20:03, 4 Jan 2025 INN_Ingrid (talk) add the structural figure and caption it properly 3,241 bytes +28 | Revision 11 — 23:03, 30 Jan 2025 StopperingSteff (talk) attribute the potency comparison to the head-to-head trial rather than to two separate ones 3,519 bytes +278 | ||
|---|---|---|---|
| 26 | Its advantage is route. For someone unwilling or unable to inject, an oral option changes what treatment is available at all, and this is the axis on which it competes rather than on effect size.{{r|drucker2018}} | 26 | Its advantage is route. For someone unwilling or unable to inject, an oral option changes what treatment is available at all, and this is the axis on which it competes rather than on effect size.{{r|drucker2018}} |
| 27 | 27 | ||
| + | 28 | The small-molecule agonists such as [[Orforglipron|orforglipron]] address the same problem differently: not being peptides, they need neither an enhancer nor fasting conditions.{{r|drucker2018}} | |
| + | 29 | ||
| 28 | == References == | 30 | == References == |
| 29 | {{reflist}} | 31 | {{reflist}} |
| ⋮ | ⋮ | ||
| 31 | <ref name="buckley2018">Buckley ST, Bækdal TA, Vegge A, et al. "Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist." ''Science Translational Medicine'' 10(467):eaar7047 (2018). PMID 30429357.</ref> | 33 | <ref name="buckley2018">Buckley ST, Bækdal TA, Vegge A, et al. "Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist." ''Science Translational Medicine'' 10(467):eaar7047 (2018). PMID 30429357.</ref> |
| 32 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 34 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| + | 35 | ||
| + | 36 | == See also == | |
| + | 37 | * [[Semaglutide]] | |
| + | 38 | * [[Orforglipron]] | |
| + | 39 | * [[GLP-1 receptor agonist]] | |
| 33 | 40 | ||
| 34 | {{DEFAULTSORT:Oral semaglutide}} | 41 | {{DEFAULTSORT:Oral semaglutide}} |